A phase I clinical study of Coronavirus vaccine

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2020 New trial record
02 Jun 2020 According to an Intravacc media release, Intravacc and EpiVax have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravaccs proprietary Outer Membrane Vesicles (OMV) technology platform.Intravacc will utilize its in-house pilot-scale facility for the GMP production of the OMV-peptide vaccine, for clinical (phase I) studies.
02 Jun 2020 According to a EpiVax media release, the company expect to initiate this study in Q4 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com